Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin
Recruitment status was Not yet recruiting
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is studying blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin.
Genetic: gene expression analysis
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
|Official Title:||Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy|
- Serum PSA values at 7 months [ Designated as safety issue: No ]
- Role of genetic variation in response to therapy [ Designated as safety issue: No ]
|Study Start Date:||February 2010|
|Estimated Primary Completion Date:||March 2010 (Final data collection date for primary outcome measure)|
- To test the association between serum PSA response (< 4 ng/mL) at 7 months with inherited variability of germline single nucleotide polymorphisms, in a set of candidate genes, in patients with metastatic prostate cancer treated with combination induction androgen-deprivation therapy comprising bicalutamide and goserelin.
OUTLINE: DNA extracted from whole blood or serum samples is analyzed for inherited variability of germline single nucleotide polymorphisms.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01120262
|Principal Investigator:||Kathleen A. Cooney, MD||University of Michigan Cancer Center|